Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,754 | $3,676 | $3,029 | $3,789 |
| % Growth | 2.1% | 21.4% | -20.1% | – |
| Cost of Goods Sold | $522 | $530 | $464 | $565 |
| Gross Profit | $3,233 | $3,145 | $2,564 | $3,224 |
| % Margin | 86.1% | 85.6% | 84.7% | 85.1% |
| R&D Expenses | $1,558 | $1,432 | $1,340 | $1,426 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $658 | $634 | $633 | $792 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$10 | $0 | $0 | $16 |
| Operating Expenses | $2,206 | $2,066 | $1,973 | $2,234 |
| Operating Income | $1,027 | $1,080 | $592 | $990 |
| % Margin | 27.3% | 29.4% | 19.5% | 26.1% |
| Other Income/Exp. Net | $737 | $439 | $313 | -$32 |
| Pre-Tax Income | $1,763 | $1,519 | $905 | $958 |
| Tax Expense | $303 | $127 | $96 | $40 |
| Net Income | $1,460 | $1,392 | $809 | $918 |
| % Margin | 38.9% | 37.9% | 26.7% | 24.2% |
| EPS | 14.09 | 13.24 | 7.58 | 8.53 |
| % Growth | 6.4% | 74.7% | -11.1% | – |
| EPS Diluted | 13.62 | 12.81 | 7.27 | 8.06 |
| Weighted Avg Shares Out | 104 | 105 | 107 | 108 |
| Weighted Avg Shares Out Dil | 107 | 109 | 111 | 114 |
| Supplemental Information | – | – | – | – |
| Interest Income | $175 | $175 | $174 | $183 |
| Interest Expense | $19 | $4 | $9 | $11 |
| Depreciation & Amortization | $137 | $135 | $127 | $126 |
| EBITDA | $1,919 | $1,657 | $1,041 | $1,095 |
| % Margin | 51.1% | 45.1% | 34.4% | 28.9% |